Patients with melanoma with BRAF mutations had higher rates of PFS and OS when treated with combination PD-1 and CTLA-4 ICIs compared with patients with wild-type BRAF in the CheckMate 067 trial (68% vs. 53% 3-year OS, respectively; ref. 69). This evidence concerns the gene CTLA4 and melanoma.